Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stone, R. M.
Right arrow Articles by Freedman, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stone, R. M.
Right arrow Articles by Freedman, A. S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 12, 2535-2542, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma

RM Stone, D Neuberg, R Soiffer, T Takvorian, M Whelan, SN Rabinowe, JC Aster, P Leavitt, P Mauch and AS Freedman
Department of Medicine, Dana-Farber Cancer Institute, Boston, MA 02115.

PURPOSE: To determine the incidence, natural history, and risk factors associated with myelodysplastic syndrome (MDS) occurring as a late complication following autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma. METHODS: We retrospectively reviewed the charts of all 262 patients who underwent autologous bone marrow transplantation for non-Hodgkin's lymphoma at the Dana-Farber Cancer Institute from 1982 through 1991. Although patients received a variety of treatments before they were eligible for transplant, identical myeloablative therapy (cyclophosphamide 60 mg/kg/d for 2 days plus total-body irradiation twice daily for 3 days) was administered in each case. By collecting data on pretransplant and early posttransplant variables, we attempted to identify risk factors for the development of MDS. RESULTS: The crude overall incidence of posttransplant MDS or acute myeloid leukemia (AML) was 7.6%. The actuarial risk at 6 years was 18% +/- 9%. The median time of onset was 31 months (range, 10 to 101) after transplant or 69 months (range, 27 to 141) after initial treatment for lymphoma. Pretreatment variables predictive for the development of MDS (univariate analysis) included prolonged interval between initial treatment and the transplant procedure (P = .003), increased duration of exposure to chemotherapy (P = .019) or to alkylating agents (P = .045), and use of radiation therapy (P = .032) or pelvic radiation (P = .003) before transplant. CONCLUSION: MDS is a potential complication of autologous bone marrow transplantation for non-Hodgkin's lymphoma; bone marrow stem-cell damage sustained before the transplant may be the most important risk factor.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. Chakraborty, C.-L. Sun, L. Francisco, M. Sabado, L. Li, K. L. Chang, S. Forman, S. Bhatia, and R. Bhatia
Accelerated Telomere Shortening Precedes Development of Therapy-Related Myelodysplasia or Acute Myelogenous Leukemia After Autologous Transplantation for Lymphoma
J. Clin. Oncol., February 10, 2009; 27(5): 791 - 798.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Kalaycio, L. Rybicki, B. Pohlman, R. Sobecks, S. Andresen, E. Kuczkowski, and B. Bolwell
Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia
J. Clin. Oncol., August 1, 2006; 24(22): 3604 - 3610.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Brown and A. S. Freedman
In Reply:
J. Clin. Oncol., November 1, 2005; 23(31): 8121 - 8122.
[Full Text] [PDF]

Home page
 JCOHome page
R. Bhatia, K. Van Heijzen, A. Palmer, A. Komiya, M. L. Slovak, K. L. Chang, H. Fung, A. Krishnan, A. Molina, A. Nademanee, et al.
Longitudinal Assessment of Hematopoietic Abnormalities After Autologous Hematopoietic Cell Transplantation for Lymphoma
J. Clin. Oncol., September 20, 2005; 23(27): 6699 - 6711.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Bhatia, L. L. Robison, L. Francisco, A. Carter, Y. Liu, M. Grant, K. S. Baker, H. Fung, J. G. Gurney, P. B. McGlave, et al.
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study
Blood, June 1, 2005; 105(11): 4215 - 4222.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Andre, N. Mounier, X. Leleu, A. Sonet, P. Brice, M. Henry-Amar, H. Tilly, B. Coiffier, A. Bosly, P. Morel, et al.
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients
Blood, February 15, 2004; 103(4): 1222 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. A. Lister
High-Dose Therapy for Follicular Lymphoma Revisited: Not If, but When?
J. Clin. Oncol., November 1, 2003; 21(21): 3894 - 3896.
[Full Text] [PDF]

Home page
 Ann OncolHome page
N. Kroger, A. R. Zander, G. Martinelli, P. Ferrante, J. M. Moraleda, G. A. Da Prada, T. Demirer, G. Socie, and G. Rosti
Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation
Ann. Onc., April 1, 2003; 14(4): 554 - 558.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. S. Baker, T. E. DeFor, L. J. Burns, N. K.C. Ramsay, J. P. Neglia, and L. L. Robison
New Malignancies After Blood or Marrow Stem-Cell Transplantation in Children and Adults: Incidence and Risk Factors
J. Clin. Oncol., April 1, 2003; 21(7): 1352 - 1358.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. O. Armitage, P. P. Carbone, J. M. Connors, A. Levine, J. M. Bennett, and S. Kroll
Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin's Lymphoma Patients
J. Clin. Oncol., March 1, 2003; 21(5): 897 - 906.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Metayer, R. E. Curtis, J. Vose, K. A. Sobocinski, M. M. Horowitz, S. Bhatia, J. W. Fay, C. O. Freytes, S. C. Goldstein, R. H. Herzig, et al.
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
Blood, March 1, 2003; 101(5): 2015 - 2023.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Hunault-Berger, N. Ifrah, and P. Solal-Celigny
Intensive therapies in follicular non-Hodgkin lymphomas
Blood, July 30, 2002; 100(4): 1141 - 1152.
[Full Text] [PDF]

Home page
 BloodHome page
G. A. Wiseman, L. I. Gordon, P. S. Multani, T. E. Witzig, S. Spies, N. L. Bartlett, R. J. Schilder, J. L. Murray, M. Saleh, R. S. Allen, et al.
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
Blood, May 29, 2002; 99(12): 4336 - 4342.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Hosing, M. Munsell, S. Yazji, B. Andersson, D. Couriel, M. de Lima, M. Donato, J. Gajewski, S. Giralt, M. Korbling, et al.
Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma
Ann. Onc., March 1, 2002; 13(3): 450 - 459.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Rambaldi, M. Lazzari, C. Manzoni, E. Carlotti, L. Arcaini, M. Baccarani, T. Barbui, C. Bernasconi, G. Dastoli, G. Fuga, et al.
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma
Blood, February 1, 2002; 99(3): 856 - 862.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. R. Wingard, G. B. Vogelsang, and H. J. Deeg
Stem Cell Transplantation: Supportive Care and Long-Term Complications
Hematology, January 1, 2002; 2002(1): 422 - 444.
[Abstract] [Full Text]

Home page
 JCOHome page
D. M. Lillington, I. N.M. Micallef, E. Carpenter, M. J. Neat, J. A.L. Amess, J. Matthews, N. J. Foot, B. D. Young, T. A. Lister, and A. Z.S. Rohatiner
Detection of Chromosome Abnormalities Pre-High-Dose Treatment in Patients Developing Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After Treatment for Non-Hodgkin's Lymphoma
J. Clin. Oncol., May 1, 2001; 19(9): 2472 - 2481.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. van Besien, M. Kelta, and P. Bahaguna
Primary Mediastinal B-Cell Lymphoma: A Review of Pathology and Management
J. Clin. Oncol., March 15, 2001; 19(6): 1855 - 1864.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Sureda, R. Arranz, A. Iriondo, E. Carreras, J.J. Lahuerta, J. Garcia-Conde, I. Jarque, M.D. Caballero, C. Ferra, A. Lopez, et al.
Autologous Stem-Cell Transplantation for Hodgkin's Disease: Results and Prognostic Factors in 494 Patients From the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group
J. Clin. Oncol., March 1, 2001; 19(5): 1395 - 1404.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Bhatia, A. D. Louie, R. Bhatia, M. R. O'Donnell, H. Fung, A. Kashyap, A. Krishnan, A. Molina, A. Nademanee, J. C. Niland, et al.
Solid Cancers After Bone Marrow Transplantation
J. Clin. Oncol., January 15, 2001; 19(2): 464 - 471.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. J. Horning, R. S. Negrin, R. T. Hoppe, S. A. Rosenberg, N. J. Chao, G. D. Long, B. W. Brown, and K. G. Blume
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial
Blood, January 15, 2001; 97(2): 404 - 409.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. C. Kluin-Nelemans, V. Zagonel, A. Anastasopoulou, D. Bron, K. J. Roozendaal, E. M. Noordijk, H. Musson, I. Teodorovic, B. Maes, A. Carbone, et al.
Standard Chemotherapy With or Without High-Dose Chemotherapy for Aggressive Non-Hodgkin's Lymphoma: Randomized Phase III EORTC Study
J Natl Cancer Inst, January 3, 2001; 93(1): 22 - 30.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. W. Press, J. F. Eary, T. Gooley, A. K. Gopal, S. Liu, J. G. Rajendran, D. G. Maloney, S. Petersdorf, S. A. Bush, L. D. Durack, et al.
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
Blood, November 1, 2000; 96(9): 2934 - 2942.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Pedersen-Bjergaard, M. K. Andersen, and D. H. Christiansen
Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
Blood, June 1, 2000; 95(11): 3273 - 3279.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. O. Armitage
Myelodysplasia and Acute Leukemia After Autologous Bone Marrow Transplantation
J. Clin. Oncol., March 1, 2000; 18(5): 945 - 945.
[Full Text] [PDF]

Home page
 JCOHome page
I. N. M. Micallef, D. M. Lillington, J. Apostolidis, J. A. L. Amess, M. Neat, J. Matthews, T. Clark, J. M. Foran, A. Salam, T. A. Lister, et al.
Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After High-Dose Therapy With Autologous Hematopoietic Progenitor-Cell Support for Lymphoid Malignancies
J. Clin. Oncol., March 1, 2000; 18(5): 947 - 947.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Krishnan, S. Bhatia, M. L. Slovak, D. A. Arber, J. C. Niland, A. Nademanee, H. Fung, R. Bhatia, A. Kashyap, A. Molina, et al.
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors
Blood, March 1, 2000; 95(5): 1588 - 1593.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Apostolidis, R. K. Gupta, D. Grenzelias, P. W. M. Johnson, V. I. Pappa, K. E. Summers, A. Salam, K. Adams, A. J. Norton, J. A. L. Amess, et al.
High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up
J. Clin. Oncol., February 1, 2000; 18(3): 527 - 527.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
F. Cabanillas, S. Horning, M. Kaminski, and R. Champlin
Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options
Hematology, January 1, 2000; 2000(1): 166 - 179.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. S. Freedman, D. Neuberg, P. Mauch, R. J. Soiffer, K. C. Anderson, D. C. Fisher, R. Schlossman, E. P. Alyea, T. Takvorian, H. Jallow, et al.
Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma
Blood, November 15, 1999; 94(10): 3325 - 3333.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. W. Friedberg, D. Neuberg, R. M. Stone, E. Alyea, H. Jallow, A. LaCasce, P. M. Mauch, J. G. Gribben, J. Ritz, L. M. Nadler, et al.
Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma
J. Clin. Oncol., October 1, 1999; 17(10): 3128 - 3135.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Aristei and A. Tabilio
Total-Body Irradiation in the Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoproliferative Diseases
Oncologist, October 1, 1999; 4(5): 386 - 397.
[Abstract] [Full Text]

Home page
 BloodHome page
E. Abruzzese, J. E. Radford, J. S. Miller, J. J. Vredenburgh, P. N. Rao, M. J. Pettenati, J. M. Cruz, J. J. Perry, S. Amadori, and D. D. Hurd
Detection of Abnormal Pretransplant Clones in Progenitor Cells of Patients Who Developed Myelodysplasia After Autologous Transplantation
Blood, September 1, 1999; 94(5): 1814 - 1819.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. C. Aisenberg
Problems in Hodgkin's Disease Management
Blood, February 1, 1999; 93(3): 761 - 779.
[Full Text] [PDF]

Home page
 JCOHome page
J. Apostolidis, J. M. Foran, P.W.M. Johnson, A. Norton, J. Amess, J. Matthews, M. Bradburn, T.A. Lister, and A. Z.S. Rohatiner
Patterns of Outcome Following Recurrence After Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma
J. Clin. Oncol., January 1, 1999; 17(1): 216 - 216.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Andre, M. Henry-Amar, D. Blaise, P. Colombat, J. Fleury, N. Milpied, J.-Y. Cahn, J.-L. Pico, Y. Bastion, M. Kuentz, et al.
Treatment-Related Deaths and Second Cancer Risk After Autologous Stem-Cell Transplantation for Hodgkin's Disease
Blood, September 15, 1998; 92(6): 1933 - 1940.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Mach-Pascual, R. D. Legare, D. Lu, M. Kroon, D. Neuberg, R. Tantravahi, R. M. Stone, A. S. Freedman, L. M. Nadler, J. G. Gribben, et al.
Predictive Value of Clonality Assays in Patients With Non-Hodgkin's Lymphoma Undergoing Autologous Bone Marrow Transplant: A Single Institution Study
Blood, June 15, 1998; 91(12): 4496 - 4503.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. J. Deeg and G. Socie
Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers
Blood, March 15, 1998; 91(6): 1833 - 1844.
[Full Text] [PDF]

Home page
 BloodHome page
A. Nademanee, A. Molina, M. R. O'Donnell, A. Dagis, D. S. Snyder, P. Parker, A. Stein, E. Smith, I. Planas, A. Kashyap, et al.
Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group
Blood, November 15, 1997; 90(10): 3844 - 3852.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. J. Horning, N. J. Chao, R. S. Negrin, R. T. Hoppe, G. D. Long, W. W. Hu, R. M. Wong, B. W. Brown, and K. G. Blume
High-Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplantation for Recurrent or Refractory Hodgkin's Disease: Analysis of the Stanford University Results and Prognostic Indices
Blood, February 1, 1997; 89(3): 801 - 813.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1994 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online